Elective Bladder-Sparing Treatment for Muscle Invasive Bladder Cancer

被引:2
|
作者
Lendinez-Cano, G. [1 ]
Rico-Lopez, J. [1 ]
Moreno, S. [1 ]
Fernandez Parra, E. [2 ]
Gonzalez-Almeida, C. [3 ]
Camacho Martinez, E. [1 ]
机构
[1] Hosp Univ Nuestra Senora Valme, Serv Urol, Seville, Spain
[2] Hosp Univ Nuestra Senora Valme, Serv Oncol, Seville, Spain
[3] Hosp Univ Nuestra Senora Valme, Unidad Estadist Metodol & Evaluac Invest, Seville, Spain
来源
ACTAS UROLOGICAS ESPANOLAS | 2014年 / 38卷 / 01期
关键词
Bladder-sparing; Bladder cancer; Radiotherapy; Chemotherapy; Transurethral; resection; BACILLUS-CALMETTE-GUERIN; TERM-FOLLOW-UP; TRANSURETHRAL RESECTION; SELECTIVE BLADDER; INFILTRATING CARCINOMA; RADICAL CYSTECTOMY; PRIMARY CISPLATIN; PRESERVATION; THERAPY; CHEMOTHERAPY;
D O I
10.1016/j.acuro.2013.03.004
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objetives: Radical cystectomy is the standard treatment for localised muscle invasive bladder cancer (MIBC). We offer a bladder-sparing treatment with TURB +/- Chemotherapy + Radiotherapy to selected patients as an alternative. Material and methods: We analyze, retrospectively, 30 patients diagnosed with MIBC from March 1991 to October 2010. The mean age was 62.7 years (51-74). All patients were candidates for a curative treatment, and underwent strict selection criteria: T2 stage, primary tumor, solitary lesion smaller than 5 cm with a macroscopic disease-free status after TURB, negative random biopsy without hydronephrosis. Staging CT evaluation was normal. Restaging TURB or tumor bed biopsy showed a disease-free status or microscopic muscle invasion. 14 patients underwent TURB alone, 13 TURB + Chemotherapy and 3 TURB + Chemotherapy + Radiotherapy. Results: The mean follow up was 88.7 months (19-220). 14 patients remained disease free (46.6%), 10 had recurrent non-muscle invasive bladder cancer (33%). 81.3% complete clinical response. 71% bladder preserved at 5-years. Overall, 5-years survival rate was 79% and 85% cancer-specific survival rate. Conclusions: Although radical cystectomy is the standard treatment for localised MIBC, in strictly selected cases, bladder-sparing treatment offers an alternative with good long term results. (C) 2013 AEU. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:7 / 13
页数:7
相关论文
共 50 条
  • [1] Bladder-Sparing Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer
    Ericson, Kyle J.
    Murthy, Prithvi B.
    Bryk, Darren J.
    Ramkumar, Rathika R.
    Broughman, James R.
    Khanna, Abhinav
    Mian, Omar Y.
    Campbell, Steven C.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (12) : 697 - 707
  • [2] Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
    Tholomier, Come
    Souhami, Luis
    Kassouf, Wassim
    [J]. TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (06) : 2920 - 2937
  • [3] Bladder-sparing treatment options in localized muscle-invasive bladder cancer
    Nason, Gregory J.
    Ajib, Khaled
    Tan, Guan H.
    Kulkarni, Girish S.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (03) : 179 - 188
  • [4] Bladder-sparing trimodal therapy for muscle invasive bladder cancer
    Khalifa, J.
    Roumiguie, M.
    Pouessel, D.
    Sargos, P.
    [J]. CANCER RADIOTHERAPIE, 2022, 26 (6-7): : 771 - 778
  • [5] Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer
    Ben -David, Reuben
    Galsky, Matthew D.
    Sfakianos, John P.
    [J]. TRENDS IN MOLECULAR MEDICINE, 2024, 30 (07) : 686 - 697
  • [6] Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer
    Nguyen, Eric K.
    Yu, Hang
    Pond, Gregory
    Shayegan, Bobby
    Pinthus, Jehonathan H.
    Kapoor, Anil
    Mukherjee, Som D.
    Neville, Alan
    Lalani, Aly-Khan A.
    Hotte, Sebastien J.
    Corbett, Thomas B.
    Dayes, Ian S.
    Lukka, Himanshu R.
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2020, 14 (04): : 122 - 129
  • [7] Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer
    de Angelis, Mario
    Basile, Giuseppe
    Scornajenghi, Carlo Maria
    Asero, Vincenzo
    Del Giudice, Francesco
    Moschini, Marco
    [J]. CURRENT OPINION IN UROLOGY, 2023, 33 (05) : 354 - 359
  • [8] MicroRNA Biomarkers for Patients With Muscle-Invasive Bladder Cancer Undergoing Selective Bladder-Sparing Trimodality Treatment
    Meng, Wei
    Efstathiou, Jason
    Singh, Rajbir
    McElroy, Joseph
    Volinia, Stefano
    Cui, Ri
    Ibrahim, Ahmed
    Johnson, Benjamin
    Gupta, Nirmala
    Mehta, Satvam
    Wang, Huabao
    Miller, Eric
    Phuong Nguyen
    Fleming, Jessica
    Wu, Chin-Lee
    Haque, S. Jaharul
    Shipley, William
    Chakravarti, Arnab
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01): : 197 - 206
  • [9] The efficacy of trimodality bladder-sparing treatment in bladder cancer
    Liebman, M. C.
    Wu, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Bladder-sparing therapy for muscle-infiltrating bladder cancer
    Vito Pansadoro
    Paolo Emiliozzi
    [J]. Nature Clinical Practice Urology, 2008, 5 : 368 - 375